{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:40:29Z","timestamp":1792809629888,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1598,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1111\/j.1524-4733.2008.00434.x","type":"journal-article","created":{"date-parts":[[2008,7,31]],"date-time":"2008-07-31T10:35:07Z","timestamp":1217500507000},"page":"217-225","source":"Crossref","is-referenced-by-count":43,"title":["Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy"],"prefix":"10.1016","volume":"12","author":[{"given":"Scott D.","family":"Ramsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Malin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan V.","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1524-4733.2008.00434.x_bib10","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29A","author":"Trillet-Lenoir","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed- dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib60","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib70","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib80","doi-asserted-by":"crossref","first-page":"557","DOI":"10.6004\/jnccn.2005.0031","article-title":"Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence","volume":"3","author":"Lyman","year":"2005","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib90","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.1999.17.11.3676","article-title":"Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology","volume":"17","author":"Bennett","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.6004\/jnccn.2005.0030","article-title":"Myeloid growth factors clinical practice guidelines in oncology","volume":"3","author":"Crawford","year":"2005","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib110","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2005.04.3281","article-title":"Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in patients with small-cell lung cancer","volume":"24","author":"Timmer-Bonte","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib120","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/jnci\/85.6.488","article-title":"Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy","volume":"85","author":"Lyman","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib130","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0959-8049(98)00222-6","article-title":"The economics of febrile neutropenia: implications for the use of colony-stimulating factors","volume":"34","author":"Lyman","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib140","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1592\/phco.24.5.488.33360","article-title":"Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy","volume":"24","author":"Cosler","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1524-4733.2005.03099.x","article-title":"Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy","volume":"8","author":"Cosler","year":"2005","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0959-8049(95)00468-8","article-title":"An economic model to assess the savings from a clinical application of haematopoietic growth factors","volume":"32A","author":"Uyl-de Groot","year":"1996","journal-title":"Eur J Cancer"},{"issue":"Suppl.7","key":"10.1111\/j.1524-4733.2008.00434.x_bib170","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/0959-8049(93)90613-K","article-title":"The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy","volume":"29","author":"Glaspy","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib180","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2165\/00019053-199711060-00005","article-title":"Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma","volume":"11","author":"Dranitsaris","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/10428199509051714","article-title":"Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma","volume":"17","author":"Dranitsaris","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib200","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0924-8579(00)00235-1","article-title":"Out-patient management of febrile neutropenia","volume":"16","author":"Talcott","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib210","first-page":"1109","article-title":"Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma","volume":"89","author":"Doorduijn","year":"2004","journal-title":"Haematologica"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib220","first-page":"394","article-title":"Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy","volume":"30","author":"Peroutka","year":"1995","journal-title":"Formulary"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib230","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1994.12.6.1245","article-title":"Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor","volume":"12","author":"Nichols","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib240","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib250","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","article-title":"Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule","volume":"10","author":"Talcott","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib260","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib270","author":"US Department of Labor"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib280","author":"Centers for Medicare and Medicaid Services"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib290","series-title":"Current Procedural Terminology (CPT). CPT 99211, CPT 90772","author":"American Medical Society","year":"2006"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib300","author":"Centers for Medicare and Medicaid Services"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib310","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/annonc\/mdl135","volume":"17","author":"Martin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib320","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib330","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib340","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00044011-200727060-00002","article-title":"Economic burden of haematological adverse effects in cancer patients: a systematic review","volume":"27","author":"Liou","year":"2007","journal-title":"Clin Drug Investig"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib350","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1185\/030079907X199790","article-title":"Economic burden of cardiovascular events and fractures among patients with end-stage renal disease","volume":"23","author":"Doan","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib360","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdm525","article-title":"Cost of neutropenic complications of chemotherapy","volume":"19","author":"Weycker","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib370","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1634\/theoncologist.12-4-478","article-title":"Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients","volume":"12","author":"Bennett","year":"2007","journal-title":"Oncologist"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib380","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib390","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib400","first-page":"394A","article-title":"Dale D, for the ANC study group. Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy","volume":"20","author":"Lyman","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib410","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1345\/aph.1G516","article-title":"Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?","volume":"40","author":"Weycker","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib420","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib430","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1200\/JCO.2005.03.9909","article-title":"Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications","volume":"24","author":"Klastersky","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib440","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1002\/cncr.21089","article-title":"Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin","volume":"103","author":"Chamilos","year":"2005","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib450","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00520-004-0614-5","article-title":"Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score","volume":"12","author":"Uys","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib460","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00520-006-0185-8","article-title":"Risk-adapted strategy for the management of febrile neutropenia in cancer patients","volume":"15","author":"Klastersky","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib490","author":"United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib500","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib510","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0140-6736(05)67110-3","article-title":"Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index","volume":"366","author":"Colleoni","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib520","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/106286060201700604","article-title":"Chemotherapy dose intensity determination as a quality of care measure for managed care organizations in the treatment of early-stage breast cancer","volume":"17","author":"Morrow","year":"2002","journal-title":"Am J Med Qual"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib530","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/sj.bjc.6601279","article-title":"Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients","volume":"89","author":"Leonard","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib540","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/1097-0142(20010915)92:6<1354::AID-CNCR1458>3.0.CO;2-P","article-title":"Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care","volume":"92","author":"Link","year":"2001","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib550","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices","volume":"21","author":"Lyman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib560","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","article-title":"30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study","volume":"330","author":"Bonadonna","year":"2005","journal-title":"BMJ"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib570","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib580","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM198101013040103","article-title":"Dose-response effect of adjuvant chemotherapy in breast cancer","volume":"304","author":"Bonadonna","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib590","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1200\/JCO.2005.12.633","article-title":"Racial disparities in treatment and survival among women with early-stage breast cancer","volume":"23","author":"Hershman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib600","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","article-title":"Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy","volume":"100","author":"Shayne","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib610","first-page":"471","article-title":"Cost effectiveness of myeloid growth factors in cancer chemotherapy","volume":"2","author":"Lyman","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib620","series-title":"Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics","article-title":"Economics of hematopoietic growth factors","author":"Lyman","year":"2004"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib630","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1200\/JCO.1998.16.7.2435","article-title":"Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer","volume":"16","author":"Silber","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib640","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.2000.18.1.72","article-title":"Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib650","first-page":"1555","article-title":"Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting","volume":"51","author":"Zbrozek","year":"1994","journal-title":"Am J Hosp Pharm"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib660","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2165\/00019053-200119110-00003","article-title":"Cost effectiveness of treatment options in advanced breast cancer in the UK","volume":"19","author":"Brown","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4170","article-title":"A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer","volume":"4","author":"Lister-Sharp","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib680","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2004.04.158","article-title":"HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis","volume":"22","author":"Elkin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib690","author":"Drugs@FDA"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib700","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1592\/phco.25.3.372.61608","article-title":"Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy","volume":"25","author":"Wong","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib710","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.1998.16.2.642","article-title":"Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients","volume":"16","author":"Steward","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib720","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1096-8652(199604)51:4<289::AID-AJH7>3.0.CO;2-S","article-title":"Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin","volume":"51","author":"Yau","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib730","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdf130","article-title":"Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer","volume":"13","author":"Holmes","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib740","first-page":"715","article-title":"A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer","volume":"10","author":"Siena","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib750","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1524-4733.2007.00242.x","article-title":"Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy","volume":"11","author":"Eldar-Lissai","year":"2008","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib760","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib770","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdm438","article-title":"Pegfilgrastim {+\/\u2212} ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study","volume":"19","author":"von Minckwitz","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib780","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2004.01.001","article-title":"The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia","volume":"50","author":"Lyman","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib790","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1001\/jama.1992.03480150061038","article-title":"Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results","volume":"267","author":"Hillner","year":"1992","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib800","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00001813-199811000-00009","article-title":"Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients","volume":"9","author":"Brown","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib810","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0029-7844(01)01624-6","article-title":"Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk","volume":"98","author":"Armstrong","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1111\/j.1524-4733.2008.00434.x_bib820","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/A:1008230000822","article-title":"The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial","volume":"8","author":"Liljegren","year":"1997","journal-title":"Ann Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510606985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510606985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T22:31:27Z","timestamp":1557700287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510606985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1098301510606985"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00434.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}